{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-119727","form_type":"8-K","ticker":"AARD","cik":"0001774857","company_name":"Aardvark Therapeutics, Inc.","filed_at":"2026-03-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.134276+00:00","generated_at":"2026-05-15T09:23:01.295399+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Aardvark Therapeutics reports FY2025 net loss $57.6M; pauses all clinical trials after cardiac signal","bullets":["Net loss $57.6M for FY2025 vs $20.6M in FY2024; cash $110.0M supports operations into Q2 2027.","Voluntary pause of Phase 3 HERO and OLE trials for ARD-101 in PWS after reversible QRS prolongation in healthy volunteers.","ARD-201 obesity trials (POWER, STRENGTH) also voluntarily paused; further guidance expected Q2 2026.","Clinical and preclinical data published in Molecular Metabolism showing ARD-101 reduced hunger and increased gut hormones.","R&D spend $48.9M in FY2025 up from $17.4M; G&A $13.8M up from $5.3M."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-119727","json":"https://secwatch.observer/filing/0001193125-26-119727.json","markdown":"https://secwatch.observer/filing/0001193125-26-119727.md","text":"https://secwatch.observer/filing/0001193125-26-119727.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1774857/000119312526119727/0001193125-26-119727-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1774857/000119312526119727/ck0001774857-20260323.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T09:23:01.295399+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}